RE:RE:RE:RE:Quick Summary The drug if it's going to work has to have an efficacious dose, at the moment hopes rest on 300mg/mm2. My guesstimate is once they have enrolled the last 6 patients they will have 13 evaluable patients that have recieved 1 or more doses above 300. I've seen companies report responders from those sorts of numbers. I think Sutro and bcyc both did that. But you are right, not having efficacy at that point is very possible and doesn't stop them moving to 1b. It seemed pretty clear to me that not only is it possible efficacy emerges only during 1b but that is exactly what they were signalling today. The efficacy could come from 1a patients that continue after the start of 1b but it seems like what they are preparing us for is efficacy not being part of the end of 1a update.
MAC7824 wrote: First time poster, long time reader. Invested in THTX (formally THERF) since 2014. I appreciate all of the insight from the posters as it has been very helpful to keep my attention on this company since THTX has done a very poor job of communicating.
I totally agree with this post, JFM. One sense I have gotten from this board is that we have been hopeful for "preliminary signs of efficacy" from Phase 1a for around 6 months now. Around that time, I spent time researching how many other companies going through a Phase 1a with a FDA fast-track designation actually release "preliminary signs of efficacy" for a trial focused on safety, and found it was incredibly rare for a company to do so. Additionally, I do not agree with this board trying to glean bits of truth from management regarding preliminary signs of efficacy, as one of the primary jobs of externally facing employees (CEO, CFO, etc.) of THTX is to act as a salesman of the company. Every company tries to sound optimistic during their earnings calls, and that is their job to do so. I think it is foolish to expect that a company that is new to the oncology scene would be the rare exception to release any signs of efficacy prior to the Phase 1b being totally finished. The wise company would hold off on releasing any data until it is absolutely bullet-proof, and I expect THTX to do that.
Having said that, I am still optimistic that THTX is on-to something in oncology. As I have read on this board previously, there are MANY companies that do not make it passed Phase 1a safety trials in oncology, and I think that should be celebrated. I anticipate there will be a small price bump in the stock price once the Phase 1a PR is sent out. I do not, however, based on today's call, believe that this board should hold out any hope for efficacy data prior to the end of Phase 1b, and anticipate THTX will shift it's tone from focusing on pre-clinical efficacy to potential future avenues now that TH1902 is deemed as safe. I also agree with JFM's point regarding the explanation around repeatedly missing timelines. Based on the evidence we have thus far, what expectation is there that the Phase 1b will not be delayed significantly? My approach to THTX's timelines over the last eight years has been to listen to it, and add at least 3 months (and sometimes 6 months) to each timeline they provide, which has been more in-line with reality.
Thank you all for the posts and I will go back to just reading now!